Decreasing levels of anti-Nef antibody correlate with increasing HIV type 1 viral loads and AIDS disease progression

Yi Ming A. Chen; Rung Huei Lin; Cheng Ming Lee; Chong Yau Fu; Shou Chien Chen; Wan Jr Syu

doi:10.1089/088922299311691

Decreasing levels of anti-Nef antibody correlate with increasing HIV type 1 viral loads and AIDS disease progression

Yi Ming A. Chen, Rung Huei Lin, Cheng Ming Lee, Chong Yau Fu, Shou Chien Chen, Wan Jr Syu

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

To study the association between anti-Gag and anti-Nef antibody reactivities and their correlations with disease progression, 174 HIV-1/AIDS patients were followed up for 1 year after they received triple therapy. The antibody reactivities were analyzed using a Western blot test with recombinant Gag and Nef proteins. The results showed that decreasing levels of anti-Gag or anti-Nef antibody correlate with disease progression defined by HIV-1 viral loads or T4 cell counts. After receiving triple treatment for 1 year, 8 of 38 (21.1%) Nef antibody-negative patients became positive, while only 9 of 125 (7.2%) Nef antibody-positive persons lost the antibody reactivity (p < 0.01). Therefore, HIV-1 Nef may serve as a clinical marker of disease progression.

Original language	English
Pages (from-to)	43-50
Number of pages	8
Journal	AIDS Research and Human Retroviruses
Volume	15
Issue number	1
DOIs	https://doi.org/10.1089/088922299311691
Publication status	Published - Jan 1 1999
Externally published	Yes

ASJC Scopus subject areas

Immunology
Virology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1089/088922299311691

Cite this

@article{6d25921c02f54fcbb9545ad2e13a75d2,

title = "Decreasing levels of anti-Nef antibody correlate with increasing HIV type 1 viral loads and AIDS disease progression",

abstract = "To study the association between anti-Gag and anti-Nef antibody reactivities and their correlations with disease progression, 174 HIV-1/AIDS patients were followed up for 1 year after they received triple therapy. The antibody reactivities were analyzed using a Western blot test with recombinant Gag and Nef proteins. The results showed that decreasing levels of anti-Gag or anti-Nef antibody correlate with disease progression defined by HIV-1 viral loads or T4 cell counts. After receiving triple treatment for 1 year, 8 of 38 (21.1%) Nef antibody-negative patients became positive, while only 9 of 125 (7.2%) Nef antibody-positive persons lost the antibody reactivity (p < 0.01). Therefore, HIV-1 Nef may serve as a clinical marker of disease progression.",

author = "Chen, {Yi Ming A.} and Lin, {Rung Huei} and Lee, {Cheng Ming} and Fu, {Chong Yau} and Chen, {Shou Chien} and Syu, {Wan Jr}",

year = "1999",

month = jan,

day = "1",

doi = "10.1089/088922299311691",

language = "English",

volume = "15",

pages = "43--50",

journal = "AIDS Research and Human Retroviruses",

issn = "0889-2229",

publisher = "Mary Ann Liebert Inc.",

number = "1",

}

TY - JOUR

T1 - Decreasing levels of anti-Nef antibody correlate with increasing HIV type 1 viral loads and AIDS disease progression

AU - Chen, Yi Ming A.

AU - Lin, Rung Huei

AU - Lee, Cheng Ming

AU - Fu, Chong Yau

AU - Chen, Shou Chien

AU - Syu, Wan Jr

PY - 1999/1/1

Y1 - 1999/1/1

N2 - To study the association between anti-Gag and anti-Nef antibody reactivities and their correlations with disease progression, 174 HIV-1/AIDS patients were followed up for 1 year after they received triple therapy. The antibody reactivities were analyzed using a Western blot test with recombinant Gag and Nef proteins. The results showed that decreasing levels of anti-Gag or anti-Nef antibody correlate with disease progression defined by HIV-1 viral loads or T4 cell counts. After receiving triple treatment for 1 year, 8 of 38 (21.1%) Nef antibody-negative patients became positive, while only 9 of 125 (7.2%) Nef antibody-positive persons lost the antibody reactivity (p < 0.01). Therefore, HIV-1 Nef may serve as a clinical marker of disease progression.

AB - To study the association between anti-Gag and anti-Nef antibody reactivities and their correlations with disease progression, 174 HIV-1/AIDS patients were followed up for 1 year after they received triple therapy. The antibody reactivities were analyzed using a Western blot test with recombinant Gag and Nef proteins. The results showed that decreasing levels of anti-Gag or anti-Nef antibody correlate with disease progression defined by HIV-1 viral loads or T4 cell counts. After receiving triple treatment for 1 year, 8 of 38 (21.1%) Nef antibody-negative patients became positive, while only 9 of 125 (7.2%) Nef antibody-positive persons lost the antibody reactivity (p < 0.01). Therefore, HIV-1 Nef may serve as a clinical marker of disease progression.

UR - http://www.scopus.com/inward/record.url?scp=0032904486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032904486&partnerID=8YFLogxK

U2 - 10.1089/088922299311691

DO - 10.1089/088922299311691

M3 - Article

C2 - 10024051

AN - SCOPUS:0032904486

SN - 0889-2229

VL - 15

SP - 43

EP - 50

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

IS - 1

ER -

Decreasing levels of anti-Nef antibody correlate with increasing HIV type 1 viral loads and AIDS disease progression

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this